BACKGROUND
==========

Heart failure (HF) is considered the last stage of heart disease and a significant cause of worldwide mortality and morbidity.[@b1-cln63_4p0479] In recent years, beta-blocking therapy has become a primary pharmacologic intervention in patients with HF. The prescription of beta-blockers arises from an abundance of evidence demonstrating that beta-blocking therapy improves survival and reduces hospitalization[@b2-cln63_4p0479], although improvement in aerobic capacity has not been proved.[@b3-cln63_4p0479]

Cardiopulmonary exercise testing is a well-established technique to evaluate peak oxygen consumption (pVO~2~) in HF patients. This variable is the best prognostic factor in HF patients, even in the beta-blocking era.[@b4-cln63_4p0479] Aerobic exercise training is also a well-established nonpharmacological method to increase pVO~2~ in HF patients. In the HF population, prescription of adequate aerobic effort relative to intensity based on heart rate (HR) is crucial to obtain both an increase in exercise capacity and a reasonable control of exercise-related risks.[@b1-cln63_4p0479]

The maximum HR adjusted for age (220 -- age) is commonly used to characterize a maximum effort in normal subjects.[@b5-cln63_4p0479] Although the HR dynamics are known in non-optimized carvedilol HF patients[@b6-cln63_4p0479], little is known in optimized beta-blocked HF patients. The aim of this study is to evaluate HR dynamics (basal, peak and the percentage increase of HR) in optimized beta-blocked HF patients compared to normal individuals during a treadmill cardiopulmonary exercise test.

MATERIALS AND METHODS
=====================

Study population
----------------

A total of 25 (76% male, 24% female) HF patients (49±11 years) having an average left ventricle ejection fraction of 30±7% (determined by echocardiography), and 14 (36% male, 64% female) sedentary normal individuals (control group) (30±6 years) were included in the study. Data were collected from March 2006 to September 2007. HF patient characteristics are listed in [Tables 1](#t1-cln63_4p0479){ref-type="table"} and [2](#t2-cln63_4p0479){ref-type="table"}. Patients with atrial fibrillation, a pacemaker, or noncardiovascular functional limitations such as osteoarthritis, chronic obstructive pulmonary disease and patients whose drug therapy was not optimized were excluded from this study. Optimization was considered to be 50 mg/day or more of carvedilol and a resting HR between 50 and 60 beats per minute, maintained for at least 3 months.[@b7-cln63_4p0479]

This protocol was approved by the Ethical Committee of Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (InCor HCFMUSP). All patients provided informed consent prior to participation.

Cardiopulmonary exercise test
-----------------------------

Patients and normal subjects were asked to refrain from both strenuous physical activities and the consumption of any stimulants (coffee, tobacco, alcohol) that could influence heart rate for 24 hours prior to the cardiopulmonary exercise test. The patients' last meals were ingested at least 2 hours before the start of the test. All subjects underwent the cardiopulmonary exercise test on a programmable treadmill (Series 2000; Marquette Electronics; Milwaukee, WI, USA) in a temperature-controlled room (21--23ºC) between 10:00 a.m. and 15:00 p.m. with a standard 12 lead continuous electrocardiogram monitor (Max 1; Marquette Electronics). Blood pressure monitoring was performed by the auscultation method. Minute ventilation (VE), oxygen uptake (VO~2~), carbon dioxide output (VCO~2~) and other cardiopulmonary variables were acquired breath-by-breath by a computerized system (Vmax 229 model, SensorMedics, Yorba Linda, CA, USA). Resting VO~2~ and HR were computed as the mean of the final 30 seconds of the resting period, while peak effort pVO~2~ and heart rate (peakHR) were the mean values of the final 30 seconds of effort before exhaustion. The respiratory exchange ratios (RER) were recorded as the averaged samples obtained during each stage of the protocol in both HF patients and normal subjects (Naughton and Balke 4.0, respectively). A satisfactory cardiopulmonary exercise test was characterized by RER\>1.05 and symptoms of maximum effort. Maximum HR predicted for age was calculated by the equation: 220 -- age.

Current medication intake
-------------------------

All HF patients were receiving a beta-blocker (carvedilol) associated with ACE inhibitors (enalapril) or angiotensin II AT1 receptor antagonists (losartan). The medication profile of the HF patient group is shown in [Table 2](#t2-cln63_4p0479){ref-type="table"}. Patients took beta-blockers, ACE inhibitors, Angiotensin II AT1 receptor antagonists and Isosorbide 5-mononitrate two times per day, one half of the daily dose in the morning (9:00 a.m.) and the other half at night (9:00 p.m.). Diuretics, digoxin and spironolactone were taken in the morning (9:00 a.m.).

STATISTICAL ANALYSIS
====================

The descriptive analysis was presented as the mean, standard deviation and 95% Confidence Interval (CI). The basal HR, percentage HR increase during cardiopulmonary test and peak HR (% maximum predicted for age) for heart failure patients and controls were normally distributed. To compare these variables, we used the unpaired student's *t*-test.

Data were analyzed using the *Statistical Package for Social Sciences* (SPSS) for Windows, v 11.5 (SPSS Inc, Chicago, Ill). Statistical significance was set at p \< 0.05.

RESULTS
=======

All subjects performed a satisfactory cardiopulmonary exercise test (RER 1.2±0.5 in normals and 1.15±1 in HF patients; p=0.42). The basal HR was lower in optimized beta-blocked HF patients (57±3 bpm) compared to controls (89±14 bpm) (p\<0.0001), as also seen with peak HR (% maximum predicted for age) (65.4±11.1% for HF and 98.6±2.2 for controls; p\<0.0001). All controls reached the maximum HR for their age, while no patients in the HF group did. Moreover, the percentage increase of HR from rest to peak exercise between HF (48±9%) and control groups (53±8%) was not different (p=0.157) ([Figure 1](#f1-cln63_4p0479){ref-type="fig"}).

DISCUSSION
==========

The main finding of this study is the observation that all controls reached the maximum HR for their age, while none of the patients in the HF group were able to do so. Moreover, no difference was seen between the percentage increase of HR from rest to peak exercise between HF and control groups.

HR variability has been studied as a non-invasive tool to assess cardiac autonomic control of the nervous system, and it is proposed to reflect the interaction of sympathetic and parasympathetic (vagal) activity.[@b8-cln63_4p0479] Exercise training in sedentary subjects affects this control, as carvedilol do in HF patients.[@b9-cln63_4p0479] The HR dynamics in optimized HF patients and the percentage of HR increase during the cardiopulmonary exercise test is unknown. Achievement of age-predicted values for maximal HR during exercise is often used as a reflection of maximal or near maximal effort (220 - age).[@b5-cln63_4p0479] This method has been questioned by some authors,[@b10-cln63_4p0479] but it is currently the most commonly-used method in the world.

In our study, all sedentary subjects in the normal group reached the maximum HR for the age in the cardiopulmonary exercise test, while no patients in the HF group were able to reach. HR increased by only 65% of the maximum age-predicted HR in the HF group and 98% in the normal group. This is in partial agreement with Mezzani et al, who observed a HR increase of 76% of the maximum age-predicted in their non-optimized beta-blocker dose HF group and a 93% of the maximum age-predicted increase in the control group. The difference in HR increase in HF patients observed by Mezzani et al and our study is attributed to carvedilol dose optimization. The HR increase in the normal group of his study was similar to our results, as expected. Brawner et al designed a study to test the hypothesis that the percentage of HR reserve (peak HR -- rest HR) was equivalent to the percentage of VO~2~ reserve during treadmill exercise among patients with a history of myocardial infarction, a group of patients with HF and a group with subjects with risk factors for heart diseases. In this study, the authors showed that the peak HR was higher in non-beta-blocked HF patients than in beta-blocked patients (143±3 bpm versus 125±4 bpm p\<0.01), while the HR reserve was the same (52±3 versus 50±3, p=NS). The authors did not calculate the percentage of HR increase or compare any of these variables with the cardiovascular risk factors group.[@b11-cln63_4p0479]

Our data suggest that the maximum HR predicted for age (220 -- age) should not be used to characterize a maximum effort in optimized beta-blocked HF patients. Despite this, the percentage increase of HR from rest to peak exercise between HF and control groups was not different. Thus, a peak HR of 65% of the maximum HR predicted for age should be considered to characterize and estimate a near-maximal effort in HF patients undergoing optimized beta-blocking therapy, rather than the currently used definition of 90 to 100% of 220-age. This equation (65% (220 -- age)) has never been evaluated previously. We hypothesized that the HR percentage increase was the same in HF patients and controls because the optimized beta-blocked HF patients started the cardiopulmonary exercise test with a basal HR (effect of carvedilol) lower than the normal group, despite the fact that the maximum HR calculated by age was not reached.

CONCLUSION
==========

In the treadmill cardiopulmonary exercise test, optimized beta-blocked HF patients had both basal and peak HRs that were lower than control. No patient in the HF group reached the maximum HR predicted by the age, despite the fact that the percentage HR increase was the same as in sedentary normal subjects. In HF patients undergoing optimized beta-blocking therapy, the maximum HR during cardiopulmonary exercise test should be set as 65% of 220 - age to characterize and estimate near-maximal effort during the exercise treadmill test. This information may also be useful in rehabilitation programs and ischemic tests, although further studies are required.

![Data are presented by mean ± 95% of confidence interval. A: Basal HR between controls and heart failure group; B: Mean of HR percentage increase between controls and heart failure group and C: Mean of peak HR (%maximum predicted for age). \* significant values (\<0.05)](cln63_4p0479f1){#f1-cln63_4p0479}

###### 

Subject characteristics

                                          Heart Failure (25)           Controls (14)                p-value
  --------------------------------------- ---------------------------- ---------------------------- ----------
  Age                                     49±11 years                  30±6 years                   \<0.0001
  Peak oxygen consumption                 19±6 mLO~2~.kg^−1^.min^−1^   31±4 mL O~2~kg^−1^ mim^−1^   \<0.0001
  Body mass index                         23±2 kg/m^2^                 22±1 kg/m^2^                 p=0.18
  Basal HR                                57±3 bpm                     89±14 bpm                    \<0.0001
  Peak HR (% maximum predicted for age)   65.4±11.1%                   98.6±2.2%                    \<0.0001
  HR percentage increase                  48±9%                        53±8%                        p=0.157

###### 

Characteristics of heart failure patients

  Characteristics of heart failure patients            Number of patients (%), dose (mg/day)
  ---------------------------------------------------- ---------------------------------------
  Etiology:                                            
   Ischemic                                            42%
   Idiopathic dilated cardiomyopathy                   44%
   Hypertensive                                        14%
  NYHA functional class:                               
   I                                                   42%
   II                                                  42%
   III                                                 16%
  Left ventricle ejection fraction                     30±7%
  Current medications:                                 
  Diuretics                                            
   Furosemide                                          64%, 52±30mg/day
   hydrochlorothiazide                                 48%, 43±24md/day
  ACE inhibitors                                       
   Enalapril                                           64%, 38±6mg/day
   Captopril                                           20%, 93±37mg/day
  Angiotensin II AT1 receptor antagonists (losartan)   16%, 75±29mg/day
  β-adrenergic receptor blocker (carvedilol)           100%, 50±0mg/day
  Spironolactone                                       28%, 25±0mg/day
  Digoxin                                              44%, 0.25±0mg/day
  Isosorbide 5-mononitrate                             20%, 56±35mg/day
